• Species Reactivity

  Mouse

• Specificity

  Detects mouse TFPI in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody shows no cross‑reactivity with recombinant human (rh) TFPI or rmTFPI-2.

• Source

  Monoclonal Rat IgG    _2A Clone # 372311

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant mouse TFPI    
  Leu29-Lys289    
  Accession # O54819

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  Recombinant Mouse TFPI (Catalog # )    
  under non-reducing conditions only

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TFPI

Tissue Factor Pathway Inhibitor (TFPI), also known as lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation (1). It is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains separated by two linker regions, and a C-terminal basic region (2). The first K domain (residues 50 to 100) inhibits coagulation factor VIIa complexed to tissue factor (TF). The second K domain (residues 121 to 171) inhibits factor Xa. The third K domain (residues 225 to 275) binds to heparin (3). The C‑terminal basic region may have several functions. For example, it plays an important role in the binding of TFPI to cell surfaces (2). The purified recombinant mouse TFPI ends at residue 289 and does not contain the last 17 residues (residues 290 to 306) in the C‑terminal region. It inhibits the activity of recombinant human Coagulation Factor VII (R&D Systems, Catalog # 2338-SE) in the presence of recombinant human Tissue Factor (R&D Systems, Catalog # 2339-PA).

• References:

1. Bai, H. et al. (2005) Thromb Haemost. 93:1055.

2. Bajaj, M.S. et al. (2001) Thromb Haemost. 86:959.

3. Mine, S. et al. (2002) Biochemistry 41:78.

• Long Name:

  Tissue Factor Pathway Inhibitor

• Entrez Gene IDs:

  7035 (Human); 21788 (Mouse)

• Alternate Names:

  convertin; EPI; EPITFPI1LACITFI; Extrinsic pathway inhibitor; LACI; Lipoprotein-associated coagulation inhibitor; TFPI; tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor); tissue factor pathway inhibitor